HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

Combinations of proteasome inhibitors and histone deacetylases (HDAC) inhibitors appear to be the most potent to produce synergistic cytotoxicity in preclinical trials. We have recently confirmed that L-carnitine (LC) is an endogenous HDAC inhibitor. In the current study, the anti-tumor effect of LC...

Full description

Bibliographic Details
Main Authors: Hongbiao Huang, Ningning Liu, Changshan Yang, Siyan Liao, Haiping Guo, Kai Zhao, Xiaofen Li, Shouting Liu, Lixia Guan, Chunjiao Liu, Li Xu, Change Zhang, Wenbin Song, Bing Li, Ping Tang, Q Ping Dou, Jinbao Liu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3527572?pdf=render

Similar Items

Similar Items